And of those three elements, the ii-key/peptide investigational results will almost certainly have to come first. Absent that we will stay stuck here for some time. And I count ‘they don’t work’ as one possible result. The NGIO spinout will still happen, GNBT will have access to funds which will enable they to jumpstart their remaining subsidiary activity...and things will go on much as if the pandemic never happened. In the event that the investigation shows strong results, it will move things forward but only incrementally. The bonanza doesn’t happen until phase three is complete and the data are published...and vaccine production and distribution begins. But that’s, what, six months off?